• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
University Hospital Muenster - Developmental Therapeutics Review - Q4 2010 Product Image

University Hospital Muenster - Developmental Therapeutics Review - Q4 2010

  • Published: December 2010
  • 43 pages
  • Global Markets Direct

University Hospital Muenster – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “University Hospital Muenster – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by University Hospital Muenster.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University Hospital READ MORE >



List of Tables
List of Figures
University Hospital Muenster Snapshot
University Hospital Muenster Overview
Key Information
Key Facts
University Hospital Muenster – Research and Development Overview
Key Therapeutic Areas
University Hospital Muenster – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University Hospital Muenster – Pipeline Products Glance
University Hospital Muenster – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University Hospital Muenster Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
University Hospital Muenster – Drug Profiles
Anthracyclines + liposomal daunorubicin + 2-CDA + AI
Product Description
Mechanism of Action
R&D Progress
Busulfan
Product Description
Mechanism of Action
R&D Progress
Cladribine
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF + stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Daunoxome
Product Description
Mechanism of Action
R&D Progress
lidocaine
Product Description
Mechanism of Action
R&D Progress
Liposomal Daunorubicin
Product Description
Mechanism of Action
R&D Progress
Testosterone Gel
Product Description
Mechanism of Action
R&D Progress
Treosulfan
Product Description
Mechanism of Action
R&D Progress
Zoledronic acid
Product Description
Mechanism of Action
R&D Progress
Azacitidine + Daunorubicin + Cytarabine
Product Description
Mechanism of Action
R&D Progress
granulocyte - colony stimulating factor (G-CSF) + erythropoetin (EPO)
Product Description
Mechanism of Action
R&D Progress
injection of hormonal male contraceptive
Product Description
Mechanism of Action
R&D Progress
University Hospital Muenster – Pipeline Analysis
University Hospital Muenster – Pipeline Products by Therapeutic Class
University Hospital Muenster Pipeline Products By Target
University Hospital Muenster – Pipeline Products by Route of Administration
University Hospital Muenster – Pipeline Products by Molecule Type
University Hospital Muenster - Dormant Projects
University Hospital Muenster – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS